Coronary artery disease is a global health problem
Management of CAD
Myocardial perfusion imaging
Fractional flow reserve
Mode of Action
Clinical efficacy
Easy to administer
Improved tolerability over adenosine
Administration in asthmatic and COPD patients
Case study 1
Case study 2
Fast Facts
- Coronary artery disease (CAD) is the leading cause of death among cardiovascular diseases, accounting for ~20% of deaths each year in both sexes.1
- Rapiscan is a selective A2A receptor agonist which effectively achieves maximal hyperemia during MPI and FFR assessment.2
- Rapiscan can induce maximal hyperemia in 30 seconds enabling fast protocols in MPI and FFR assessment.2
- Rapiscan is administered as a single fixed injection into a peripheral vein; no dose adjustments are required for bodyweight, elderly, renal or hepatic insufficiency.2
- The only approved hyperaemic pharmacological stress agent for the measurement of fractional flow reserve (FFR).2
- Rapiscan maintains hyperemia from ~3 minutes to more than 10 minutes2
- Rapiscan is well tolerated2 and is associated with lower degree AV block than adenosine.3
- Rapiscan can be used, with caution, in asthmatic patients and those with chronic obstructive pulmonary disease (COPD).2
1. European Heart Network. European Cardiovascular Disease Statistics 2017. Available at: www.ehnheart.org/cvd-statistics.html (Last accessed March 2022).
2. GE Healthcare. Rapiscan Summary of Product Characteristics, December 2021.
3. Azzouz MS et al. J Am Coll Cardiol 2015; 66(15); B118–B119.
Prescribing Information
Please see Rapiscan Prescribing Information for United Kingdom
Please see Myoview Prescribing Information for United Kingdom
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to GE Healthcare at gpv.drugsafety@ge.com. |
01-2022 JB01480UK